J.J., C.D., C.B., and D.F. v. Ashlynn Marketing Group, Inc.

Summary

The United States District Court for the Southern District of California grants in part and denies in part Ashlynn Marketing Group, Inc.’s Rule 12(b)(6) motion to dismiss a consolidated putative class action concerning alleged nondisclosure of the addictive potential of kratom products. The court rejects federal preemption of the plaintiffs’ California and New York consumer-protection and fraud claims and addresses standing and class-certification issues involving claims under other states’ laws. The excerpt does not include the order’s issuance date or final page number.

Holdings

1. The FDCA does not impliedly preempt plaintiffs' state-law claims because defendant could comply with both federal and state law by avoiding false, misleading, or deceptive statements and omissions concerning kratom's addictive potential.
2. The nationwide class allegations cannot be maintained because material variations among the consumer-protection and fraudulent-omission laws of the states defeat predominance under California's governmental-interest choice-of-law test.
3. At the pleading stage, the named plaintiffs have standing to assert claims involving kratom products they did not personally purchase because plaintiffs adequately alleged that the products and their alleged misrepresentations were substantially similar.
4. Plaintiff D.F. adequately pleaded claims under New York General Business Law sections 349 and 350 because the complaint plausibly alleged that consumers could not reasonably obtain comprehensible information about kratom's addictive potential before purchase.
5. Plaintiff D.F. adequately pleaded a New York fraudulent-omission claim because the complaint plausibly alleged that defendant possessed superior knowledge of kratom's addictive potential and knew consumers were acting under mistaken knowledge.
6. Plaintiff C.B. adequately pleaded that defendant owed a duty to disclose the addictive potential of its kratom products, including under the exclusive-knowledge and unreasonable-safety-hazard theories.
7. Plaintiff C.B. adequately pleaded that monetary relief was inadequate to remedy the alleged risk of future physical harm to consumers, permitting the UCL claim for public injunctive relief to proceed.
8. Leave to amend the nationwide class allegations was properly denied because the identified predominance and choice-of-law defect could not be cured through additional pleading.

Questions Presented

1. Whether plaintiffs' state-law consumer-protection, false-advertising, and fraudulent-omission claims were impliedly preempted by the Federal Food, Drug, and Cosmetic Act.
2. Whether the named plaintiffs could assert claims under the laws of states other than California and New York.
3. Whether the nationwide class allegations could be dismissed and stricken at the pleading stage because material differences among the states' consumer-protection laws defeated predominance.
4. Whether plaintiffs had standing to assert claims based on website representations they did not see or rely on.
5. Whether plaintiffs had standing to assert claims involving kratom products they did not personally purchase.
6. Whether Plaintiff D.F. adequately pleaded claims under New York's consumer-protection and false-advertising statutes and common-law fraudulent omission doctrine.
7. Whether Plaintiff C.B. adequately pleaded California UCL, CLRA, and fraudulent-omission claims based on defendant's alleged duty to disclose kratom's addictive potential.
8. Whether Plaintiff C.B. adequately pleaded that monetary damages were inadequate to support a request for public injunctive relief under the UCL.
9. Whether the nationwide class allegations could be amended.

Disposition

other